The same group also reported a case of a normozoospermic 30-year-old patient treated for BRAF-negative stage IV metastatic melanoma, who developed azoospermia (Sertoli cell-only syndrome) two years after combined treatment with anti-PD1 and anti-CTLA4 (ipilimumab/nivolumab) [69]. Here, CTLA4 is linked to metastatic melanoma.